<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The human herpesvirus Epstein-Barr virus (EBV) establishes latency and promotes the long-term survival of its host B cell by targeting the molecular machinery controlling cell fate decisions </plain></SENT>
<SENT sid="1" pm="."><plain>The cellular antiapoptotic bfl-1 gene confers protection from <z:mpath ids='MPATH_3'>apoptosis</z:mpath> under conditions of growth factor deprivation when expressed ectopically in an EBV-negative Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-derived cell line (B </plain></SENT>
<SENT sid="2" pm="."><plain>D'Souza, M </plain></SENT>
<SENT sid="3" pm="."><plain>Rowe, and D </plain></SENT>
<SENT sid="4" pm="."><plain>Walls, J </plain></SENT>
<SENT sid="5" pm="."><plain>Virol </plain></SENT>
<SENT sid="6" pm="."><plain>74:6652-6658, 2000), and the EBV latent membrane protein 1 (LMP1) and its cellular functional homologue CD40 can both drive bfl-1 via an NF-kappaB-dependent enhancer element in the bfl-1 promoter (B </plain></SENT>
<SENT sid="7" pm="."><plain>N </plain></SENT>
<SENT sid="8" pm="."><plain>D'Souza, L </plain></SENT>
<SENT sid="9" pm="."><plain>C </plain></SENT>
<SENT sid="10" pm="."><plain>Edelstein, P </plain></SENT>
<SENT sid="11" pm="."><plain>M </plain></SENT>
<SENT sid="12" pm="."><plain>Pegman, S </plain></SENT>
<SENT sid="13" pm="."><plain>M </plain></SENT>
<SENT sid="14" pm="."><plain>Smith, S </plain></SENT>
<SENT sid="15" pm="."><plain>T </plain></SENT>
<SENT sid="16" pm="."><plain>Loughran, A </plain></SENT>
<SENT sid="17" pm="."><plain>Clarke, A </plain></SENT>
<SENT sid="18" pm="."><plain>Mehl, M </plain></SENT>
<SENT sid="19" pm="."><plain>Rowe, C </plain></SENT>
<SENT sid="20" pm="."><plain>GÃ©linas, and D </plain></SENT>
<SENT sid="21" pm="."><plain>Walls, J </plain></SENT>
<SENT sid="22" pm="."><plain>Virol </plain></SENT>
<SENT sid="23" pm="."><plain>78:1800-1816, 2004) </plain></SENT>
<SENT sid="24" pm="."><plain>Here we show that the EBV nuclear antigen 2 (EBNA2) also upregulates bfl-1 </plain></SENT>
<SENT sid="25" pm="."><plain>EBNA2 trans-activation of bfl-1 requires CBF1 (or RBP-J kappa), a nuclear component of the Notch signaling pathway, and there is an essential role for a core consensus CBF1-binding site on the bfl-1 promoter </plain></SENT>
<SENT sid="26" pm="."><plain>trans-activation is dependent on the EBNA2-CBF1 interaction, is modulated by other EBV gene products known to interact with the CBF1 corepressor complex, and does not involve activation of NF-kappaB </plain></SENT>
<SENT sid="27" pm="."><plain>bfl-1 expression is induced and maintained at high levels by the EBV growth program in a lymphoblastoid cell line, and withdrawal of either EBNA2 or LMP1 does not lead to a reduction in bfl-1 mRNA levels in this context, whereas the simultaneous loss of both EBV proteins results in a major decrease in bfl-1 expression </plain></SENT>
<SENT sid="28" pm="."><plain>These findings are relevant to our understanding of EBV persistence, its role in malignant disease, and the B-cell developmental process </plain></SENT>
</text></document>